Seaport Therapeutics, that has been founded by PureTech Health, has announced that it has raised USD 225 million from General Atlantic and other investors like Third Rock Ventures, Sofinnova Investments, and ARCH Venture Partners.
This company is now backed by some of the biggest and largest Venture capitalists in drug development, and the company is now aiming to disrupt the psychiatric drugs market.
Overall, to date, Seaport Therapeutics has raised around $325M in venture capital funding, and after this Series B financing round, PureTech Health will retain 36% of the shares of Seaport Therapeutics. In the past, PureTech Health has made many remarkable disruptions in the biotechnology sector.
With this mega funding, Seaport Therapeutics, which is working on generalized anxiety disorder and major depressive disorder treatment using therapeutics, will try to make major advancements.
Daphne Zohar is the CEO, Founder, and Board Member of Seaport Therapeutics, and previously she has served as the CEO of PureTech Health and has been recognized as one of the top innovators and leaders in the Biotechnology field.
Swastik Saraf is the Founder and Managing Editor of TheMedSector. With a background in data journalism and healthcare research, he specializes in aggregating public health metrics, analyzing institutional data, and mapping out regional healthcare infrastructure. Swastik leads the data compilation team at TheMedSector, ensuring all directory tracking is built on verified primary sources before undergoing formal clinical review.
